The Texas Medical Center has named its second cohort for its United Kingdom-focused health tech accelerator. Photo via TMC

For the second time, an accelerator backed by the United Kingdom and hosted by Texas Medical Center Innovation has named 16 companies to its new cohort.

In partnership with Innovate UK, TMC named the new cohort companies in an announcement this week. The companies are divided into two categories — digital health and medical device — and cover a wide range of specialties, from diagnostics and AI monitoring to non-surgical management and more.

The accelerator launched last year with its inaugural cohort with the mission of helping companies make their United States expansion by way of the TMC.

"The first cohort of startups in our accelerator program experienced TMC's capabilities in developing and advancing solutions through cross-collaboration with top minds in clinical care, commercialization and innovation," Devin Dunn, head of the Accelerator for Health Tech at TMC, says in a news release. "We are excited to continue our partnership with Innovate UK and welcome this second cohort to continue our efforts advancing life sciences technologies across the globe."

This year's program begins June 4 and will run through November. According to the TMC, last year's cohort had significant success tapping into the health tech ecosystem in Houston, including engaging with investors, setting up a go-to-market strategy, and making inaugural U.S.-based hires.

“Our Global Incubator Programme selects driven and ambitious innovators looking to scale their technologies globally," adds Jon Hazell, partnership manager for the North America and Global Incubator at Innovate UK. "We are excited for our second cohort of startups to join the programme, supported by the Texas Medical Center accelerator, where world-class mentors and programming will help our entrepreneurs understand and meet the requirements of different markets, and build the necessary partnerships, collaborations, and networks, facilitating their entry into global markets."

The selected medical device companies — and their technologies, as described by the TMC — include:

  • Cytecom – infectious diagnostic test, powered by cutting-edge optical electrophysiology, detects resistant bacteria in just 45 seconds, enabling doctors to prescribe targeted antibiotics in minutes instead of days
  • Heartfelt Technologies Ltd – the future of heart failure telemonitoring an automatic, AI supported, non-contact telemonitoring solution for heart failure patients
  • Neurovalens Ltd – creates wearable neurostimulaton devices that treat a range of conditions in an entirely non-invasive and drug-free way
  • Oxford Medical Products Limited – a proprietary hydrogel pill that acts as a non-surgical, non-pharmacological obesity treatment that will redefine the obesity treatment market
  • Phenutest – a rapid point-of-care diagnostic test for urinary tract infection, that confirms infection and appropriate antimicrobial to prescribe within 60 minutes
  • Plexaa – world's first fully wearable, sensor controlled, bra insert that can deliver safe supraphysiological preconditioning to the breast skin the night before surgery at home
  • SolasCure Limited – a wound Gel that acts as a single, effective and easy-to-use solution to overcome the challenges to transform chronic wound care
  • Trueinvivo Limited – a proprietary dosimetry (radiation measurement) system to ensure the precision and accuracy of cancer radiotherapy

The selected digital health companies — and their technologies, as described by the TMC — include:

  • Axon Diagnostics – offers a suite of solutions to support the needs of modern day diagnostic imaging services, supporting happier lives for clinicians and helping deliver better diagnostic care for all
  • Kheiron Medical Technologies – regarded as a world leader in the development of AI-enabled cancer diagnostics and monitoring
  • KiActiv – a technology-enabled digital health model for behaviour change and self-care that rethinks exercise and makes everyday movement an effective personalized medicine for better clinical outcomes
  • Memory Lane Games – turns memories into games, offering care providers a simple, fun dementia engagement app designed to trigger positive memories and improve socialisation with caregivers and people living with dementia
  • NeuroVirt Limited – combines immersive VR, AI and computer vision to gamify rehabilitation and quantify patient impairment and improvement
  • Newton’s Tree – enables healthcare providers to procure, integrate, and monitor third party AI products as part of routine care pathways through its enterprise AI platform
  • SERG Technologies – uses patented sensor technology and artificial intelligence to transform disease management into a continuous, data driven, and patient specific approach for people with Parkinson’s
  • Thymia – leverages speech, video, and behavioral analytics gathered via specially designed video games to diagnose conditions like depression, anxiety, and ADHD, alongside critical symptoms like fatigue, mood fluctuations, and memory issues, creating novel mental health biomarkers
The partnership between the U.K. and TMC began in 2018 as a biobridge between the two entities. TMC has expanded into new biobridges with other countries — most recently with The Netherlands — and also has a Danish accelerator that's also running its second cohort this summer.
The Texas Medical Center Innovation Factory has named the 16 companies making up the inaugural cohort in the Innovate UK Global Incubator Programme. Photo via tmc.edu

TMC names inaugural cohort for unique accelerator with UK

coming to HOU

Sixteen digital health and medical device startups founded in the United Kingdom have been selected for a customized accelerator at the Texas Medical Center's Innovation Factory.

In partnership with Innovate UK, TMCi created the Innovate UK Global Incubator Programme, a new accelerator that supports UK businesses as they build their United States go-to-market plan. The program builds the BioBridge relationship between TMC and the UK that was originally established five years ago.

“The TMC UK BioBridge program was launched with the UK Department for Business and Trade in 2018 to serve as a gateway for advancing life sciences and foster innovation and research between our two countries," says Ashley McPhail, chief external affairs and administration officer for TMC, in a news release. "We saw an opportunity to work with Innovate UK to develop a larger program with the UK after the success of the 11 companies that previously participated in our health tech accelerator."

The 16 companies will participate in the program from June to November. The cohort is expected to arrive in Houston on June 5 and have access to TMCi's facilities, network of mentors and potential clients, funding, potential customers, and curated programing — all while being a unique entry point into the US. The new offering joins three other globally recognized curriculums: Biodesign, Accelerator for Cancer Therapeutics, and Health Tech.

“TMCi nurtures long-term growth, development, and competitiveness to increase startups chances of success and global expansion," says Emily Reiser, associate director of TMC Innovation. "By bringing their novel technologies and exposing them to a curated selection of TMC’s expert network, startups receive support and evaluation to build, scale, and expand in the US market."

Two of the cohort's specialties include cardiovascular and oncology — two of TMC's strongest areas of expertise — with solutions ranging from surgical devices to AI-enabled risk stratification and hospital efficiency.

Innovate UK is the country's national innovation agency dedicated to supporting business-led innovation in all sectors.

“The United Kingdom is fully committed to improving global healthcare through scientific collaboration," says His Majesty’s Consul General in Texas Richard Hyde in the release. "Through the expansion of the TMC UK BioBridge and in partnership with Innovate UK, this programme will help to expose the brightest and best British companies to the world’s largest medical city. Our companies will collaborate and grow as they work to develop cutting edge technology. The partnership between the UK Government and TMC demonstrates that international collaboration can drive both economic growth and improvement to quality of life.”

The 16 companies making up the inaugural cohort are as follows, according to TMC.

  • AINOSTICS aims to revolutionize the treatment and prevention of neurological conditions, such as dementia, by developing innovative AI-enabled solutions that draw novel insights from routinely acquired non-invasive medical scans to deliver accurate diagnosis and outcome prediction, and in turn facilitate personalized care and timely access to disease-modifying treatments for patients.
  • Alvie is a blended human plus AI-enabled digital solution providing personalised pre and rehabilitation coaching and supportive care for cancer and surgery. Alvie's technology combines data profiling, risk-stratification and tailored prescriptions of health and well-being with curated educational content, targeted behaviour change coaching and expert support through chat messaging and virtual consultations.
  • C the Signs™ is a validated AI cancer prediction platform, which can identify patients at risk of cancer at the earliest and most curable stage of the disease. Used by healthcare professionals, C the Signs can identify which tumor type a patient is at risk of and recommend the most appropriate next step in less than 30 seconds. The platform has detected over 10,000 patients with cancer, with over 50 different types of cancer diagnosed, and with a sensitivity of >98% for cancer.
  • At PEP Health, We believe all patients deserve the best care possible. Our cutting-edge machine-learning technology enables healthcare organisations, regulators, and insurers the real-time, actionable insights they need to have a direct and dramatic impact on patient experiences.
  • PreciousMD improves the lives of lung-cancer and other lung-related illnesses patients worldwide by enabling imaging-based diagnostics needed for personalized treatment pathways.
  • Ufonia is an autonomous telemedicine company, we use large language models and voice AI to increase the capacity of clinical professionals.
  • My mhealth offers digital therapeutics for a range of long-term conditions- COPD, Asthma, Diabetes and Heart Disease. Our product has been successfully deployed in the UK and India, with >100,000 users registered to date. Our solutions empower patients to self-manage their conditions, resulting in dramatic improvements in outcomes, as evidenced through multiple clinical trials and real-world evaluations.
  • At Surgery Hero, we offer a clinically backed solution that ensures whole-human support before and after surgery. We help health systems, employers and health plans cut costs without sacrificing quality of care.
  • Panakeia's software platform enables extremely rapid multi-omics profiling in minutes directly from routinely used tissue images without needing wet lab assays.
  • QV Bioelectronics are striving to deliver longer, better quality lives for brain tumour patients. Using their first-of-its-kind implantable electric field therapy device, GRACE, QV will provide effective, focal & continuous treatment without impacting patient quality of life.
  • 52 North is a med-tech company focused on improving health outcomes and health equity by reinventing care pathways. The NeutroCheck® solution is a finger-prick blood test and digital platform built to significantly improve safety and quality of life for cancer patients, by helping to identify at-home those patients who are at risk of the most fatal side-effect of chemotherapy: neutropenic sepsis.
  • Somnus is fulfilling an unmet need in global healthcare by developing real-time, point of care blood propofol monitoring. Its products will improve the care of sedated and anaesthetised patients, save money for hospitals, and facilitate a major reduction in greenhouse gas emissions.
  • ScubaTx is a breakthrough organ transplant preservation company established to solve the global unmet need for cost-efficient and longer-duration organ preservation technology. ScubaTx has developed a simple, small and affordable device which uses Persufflation to extend the preservation of organs.
  • IBEX is on a mission to help people live active, healthy and productive lives by increasing their access to early diagnosis of osteoporosis. The IBEX BH software as medical device delvers routine, automated assessment of fracture risk from routine radiology for earlier detection and more equitable treatment of osteoporosis.
  • NuVision produces products derived from donated human amniotic membrane that are used in ophthalmology to help patients with chronic, traumatic and post-surgical wounds of the eye to be treated earlier and recover more fully and more quickly. The company’s products are also used in the management of dry eye disease, a debilitating conditions that affects around 17m people in the USA.
  • Calon Cardio-Technology is on a mission to improve quality of life for patients with Left Ventricular Assist devices (LVAD) and reduce the common post operative complications associated with these implantable heart pumps. We plan to do this by introducing a completely wireless heart pump system and augment patient follow-up with built-in remote monitoring capabilities.
A new program established at TMC in partnership with Denmark will support the growth of three health tech companies. Photo courtesy of TMC

TMC launches co-hosted health tech accelerator with Denmark

biobridge support

Years ago, the Texas Medical Center established a biobridge to exchange technology and support with Denmark. Now, the two organizations are coming together to advance three health tech startups through a unique accelerator.

TMC and Denmark-based BioInnovation Institute announced today that three companies from BII will join a customized accelerator program that will guide them toward a United States go-to-market strategy. The program will be built off of the TMCi Health Tech Accelerator program.

“At TMC, we are elevating our ability to create curated go-to-market experiences for hand-selected companies that have a relationship with our partners at the BioInnovation Institute and that are seeking to prepare for of market expansion in the U.S.,” says Emily Reiser, associate director of TMC Innovation, in a news release. “We are excited about the opportunity to collaborate with BII and these founders.”

The three startups will head to Houston next week and incubate for six months, working with TMCi advisers and mentors on their individual challenges within commercialization and U.S. expansion. The three companies in the program are:

  • Aiomic, which is developing Aiomic360, an AI platform for postoperative complications. "With automated tracking and real-time risk assessment, Aiomic360 will function as a quality management tool for hospitals, a decision support tool for healthcare practitioners, and an individualized patient empowerment tool for surgical candidates," per the release.
  • Also tapping into AI, Orbit Health's solution, Neptune, is using motion data from smartwatches to track Parkinson’s motor state and treatment response passively. "Its continuous and objective insights enable regular treatment personalization that is needed throughout the course of the disease to optimize patient outcomes and improve quality of life," reads the release.
  • HEI Therapeutics is enabling at-home hypothyroidism management. "The innovative solution includes a patented finger stick blood test and digital patient empowerment tools and aims to significantly reduce the share of patients that is poorly regulated with medication," according to the release.

The TMC and the Ministry of Foreign Affairs of Denmark launched the Biobridge in 2019. BII is a nonprofit organization with a few resources — the Bio Studio, Venture Lab, and Venture House — that support life science startups with resources and even funding of up to €3 million per projects and €1.8 million per company.

“As we strengthen our offering to support visionary healthcare innovators to develop products and solutions to address clear unmet needs, our partnership with Texas Medical Center allows BII startups to gain exposure to US market and ready themselves for US market entry. We are thrilled about this collaboration with the Texas Medical Center which is one of the largest life science ecosystems in the world,” says Tony Cheng-fu Chang, principal at BioInnovation Institute. “Through the customized accelerator program, these three healthcare startups will acquire critical insight to create field-ready plans for bringing their products and solutions to the US market.”

Insight Surgery is opening its first international location, and the UK company chose Houston for it. Photo via 3dlifeprints.com

UK personalized surgery startup rebrands, expands to US by way of Houston

crossing the atlantic

An innovative health tech company headquartered in the United Kingdom has made its entrance into the United States — and Houston's Texas Medical Center is where it's setting up shop.

The company, newly renamed to Insight Surgery — neé 3D LifePrints — was originally established in 2011 by Paul Fotheringham as a social enterprise to create 3D printed prosthetics for amputees in Kenya. While the company still provides this care to developing countries, Fotheringham, who serves as CTO, evolved his mission into a business in 2015. The company is gearing up for its next evolution — starting with its first international expansion.

“We’re pivoting away from being a 3D printing company toward a company that personalizes surgery,” Fotheringham tells InnovationMap.

Insight Surgery's focus now is to provide digital planning for surgeons and create personalized medical devices. All the technology the company is working with is FDA approved, but will be customized for patients and surgeons. Previously, this type of customized care could take weeks or months, Fotheringham says, but with Insight Surgery's technology, they can accomplish this in a matter of days.

“We’ve coupled this all together at the point of care by putting people and technology in the hospitals,” Fotheringham explains. “We are changing the norm about (traditional surgery)."

Fotheringham and his team connected with Texas Medical Center Innovation Hub by way of a biobridge — an initiative by TMC to work with international entities to provide an exchange of tech and innovative care. TMC originally launched this UK partnership in 2018 and has expanded it to other countries, including Ireland, Australia, and Denmark.

Insight Surgery is currently building out its 5,000-square-foot space in TMCi that will have a print room for manufacturing. Local operations will be led by David Collins, US engineering lead, who will collaborate with Houston medical professionals at the point of care.

"The US is about 45 percent of the global market for personalized devices, so for us it's part of our expansion — both revenue and investment. We're moving into our fourth round of investment, and the funds will be used for geographic expansion," Fotheringham says. "It's the right time. There's not a lot of competitors."

These three health tech startups are moving on in TMCi's accelerator program. Photo courtesy of TMC

TMC names 3 startups to Houston health tech accelerator

onboarding tech

Thee Texas Medical Center named three companies to its accelerator program. The health tech startups will join the program and make key connections to grow their technology and business.

Texas Medical Center Innovation announced this year's cohort for the TMC Innovation Accelerator for HealthTech. The companies attended TMCi's boot camp earlier this year before being named to the cohort.

“It is always exciting to introduce a new group of talented entrepreneurs into our community,” says Tom Luby, director of TMC Innovation, in a news release. “Each with their own goals, and at their individual stage, we’ll work closely together to help them learn, grow and navigate this rich clinical landscape. We are honored to be the bridge between these innovators and the world’s largest medical city.”

The selected startups include Oxford, United Kingdom-based CardMedic, which joins the program by way of TMC's UK BioBridge, an international partnership established to bring cutting-edge health tech startups to the United States by way of Houston. The company's technology is a digital "One Stop Communication Shop" — an extensive library of pre-written scripts that help staff and patients communicate across any barrier, including language, deafness, cognitive impairment, or disability.

“The opportunity to connect with Texas Medical Center member institutions, understand their problem domain, and in what ways that may differ from the United Kingdom is invaluable. We are really excited about learning from the expert team of strategic advisors at the TMCi Accelerator about areas we needed to focus on to grow our company in the United States,” says Rachael Grimaldi, co-founder and CEO of CardMedic.

Chicago-based CareAdvisors, which helps hospitals and clinical social workers connect patients to the best resources and benefits to address social care needs, also joins the TMCi accelerator. The company's technology, the Social Care Automation tool, enables hospitals to generate revenue from preventive health programs and helps health plans reduce overutilization by putting the focus on preventive care.

Roboligent, based in Austin, designs and manufactures robotic and automated physical therapy exercises for patients with upper and lowers limb musculoskeletal issues. This robotic-assisted rehab help promotes recovery while increasing rehab centers’ operational efficiency.

“Introducing a new and innovative product, especially in the medical device field, is a thorough and collaborative effort,” says Bongsu Kim, founder and CEO of Roboligent, in a news release. “TMC’s HealthTech Accelerator is the perfect place to make connections with experts and stakeholders to help guide us in reaching our next milestone.”

The TMC has announced its latest Biobridge with Ireland and a new biodesign program with Australia. Photo courtesy of TMC

Texas Medical Center announces 2 international innovation-focused collaborations

gone global

The Texas Medical Center announced two new partnerships with international entities recently — both will bring innovative opportunities to the Houston area.

Enterprise Ireland, the country's trade and innovation agency, has entered into a strategic agreement with TMC to create the TMC's fourth biobridge. The new partnership will create gateway for Irish innovators to collaborate with the TMC to solve global health challenges.

“The breakthrough technology and entrepreneurship that is coming out of Ireland is truly impressive, and the TMC team is thrilled to be in Ireland today to solidify our partnership,” says William McKeon, president and CEO of the Texas Medical Center, in a news release. “The past two years has shown the importance of collaboration at a global scale, and we are eager to start our work with Enterprise Ireland’s team to further global innovation and research.”

Joining similar partnerships the TMC has with Denmark, the United Kingdom, and Australia, the new Irish Biobridge will focus on advancing health and life science through commercialization, innovation, and research — including identifying opportunities for clinical research and clinical trial activities, according to the release.

“The size, scale and reputation of Texas Medical Center brings new opportunities for Irish companies to innovate and scale and enter the US market,” says Leo Clancy, CEO of Enterprise Ireland, in a statement. “I am delighted to officially launch this partnership with TMC. Enterprise Ireland places a strong focus on driving innovation in the medtech industry and facilitating successful partnerships between Irish companies and influential global healthcare systems.”

Galway, Ireland-based LifeLet Medical, which is developing a novel biomimetic leaflet material for heart valve replacements, is part of TMC’s Accelerator program and is supported by Enterprise Ireland. Two other cohort companies — InVera Medical and Aurigen Medical — have been awarded funding under Irish government’s Disruptive Technologies Innovation Fund administered by Enterprise Ireland.

Also made official today is a new partnership between TMC Biodesign and Biodesign Australia, an organization led by The University of Western Australia that allows Biodesign collaboration across Perth, Melbourne, Sydney, Adelaide, and Brisbane. Australia has collaborated closely with the TMC since the country established its Biobridge in 2018. The two programs' founders and entrepreneurs will be provided with access to talent, clinical trial activity, expanded funding opportunities and market access, according to a news release.

“The launch of the Australian BioBridge in 2018 created a unique opportunity for the exchange of ideas, research and investment to advance medical breakthroughs both at Texas Medical Center and in Australia,” McKeon says in the release. “This expanded relationship with Biodesign Australia offers global opportunities for a new group of healthcare leaders, and we are excited to work collaboratively to provide a platform for innovation and commercialization.”

TMC Biodesign, which launched in 2015, helps connect health tech innovators and founders with mentors, business leaders, and technical expertise to take life-saving technologies to scale. The two programs have trained hundreds of health tech innovators.

“Biodesign Australia is thrilled to partner with Texas Medical Center in our shared goal of furthering healthcare innovation and entrepreneurship,” says Professor Kevin Pfleger, director Biomedical Innovation at The University of Western Australia, in the release. “By uniting the programming, talent and expertise found at Biodesign Australia and TMC, we are creating a dynamic ecosystem that will help to shape the future of healthcare.”

The TMC | Australia Biobridge has co-designed the Healthcare Activator — a program that allows Australian Digital Health and Medical Device companies to tap into Texas Medical Center Innovation programs and partners. Applications are now open for the inaugural cohort launched.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston-based equitable entrepreneurship tech platform expands programs

coming soon

Fresh off of celebrating the dismissal of a lawsuit from former Trump Administration officials, Hello Alice is expanding some of its offerings for entrepreneurs.

In partnership with top organizations — like Progressive, Antares Capital, Wells Fargo, and FedEx — Hello Alice has added new offerings for its 2024 Boost Camp programs, a mix of skill-building support and grant opportunities.

“We are fortunate to continue working with great enterprise partners who share our commitment to supporting Main Street through crucial grants and mentorship programs,” Carolyn Rodz, CEO and co-founder of Hello Alice, says in a news release. “Small businesses drive our economy, yet often lack the necessary financing and resources. By partnering with major companies, Hello Alice is ensuring that small businesses have access to the tools and opportunities they need to thrive and create jobs in their local communities. Together, we are building a robust support system that fosters innovation and growth for small businesses across the country.”

This year's programs, according to Hello Alice, are as follows:

  • Antares Capital REACH Cohort: The Antares REACH Grant Program provides $20,000 grants to small businesses. Grant recipients will also take part in Antares’ Growth Track Boost Camp program, a digital community which will be home to monthly business coaching workshops, mentorship, networking, and more. Applications are open until June 28, and the program begins August 8.
  • Progressive Driving Small Business Forward Grant & Booster Camp Program: Progressive is dedicating $1 million to award 20 deserving businesses with a $50,000 grant each. Grant recipients will be invited to attend an exclusive 12-week virtual Boost Camp coaching program. Applications have closed for the program beginning September 10.
  • Wells Fargo: Wells Fargo is supporting four virtual accelerator programs over the next 18 months, designed to support up to 500 participants for each program, with a focus on business health and credit-building practices. Applications will be announced this summer for the program, which will begin in early fall.
  • FedEx: The FedEx Entrepreneur Fund supports entrepreneurs in the United States by providing them with the necessary funding, resources, and networks to enhance the success of their businesses, including the Boost Camp coaching program.
  • Applications will be announced this fall for the program, which will begin in the winter.

More information and application access is available online.

Last year's Boost programs benefitted 100 small businesses, according to Hello Alice, which reported that the 2023 Antares REACH Cohort resulted in 60 percent of participants seeing an increase in their Business Health Score and 93 percent felt better equipped to confront challenges and capitalize on opportunities. In the end, 85 percent of participants feeling more optimistic about their business growth prospects.

"Hello Alice is proud to partner with high-level enterprise companies to empower small businesses and foster their success," Natalie Diamond, vice president of business development at Hello Alice, adds. "Together, we are creating unparalleled opportunities for entrepreneurs to achieve brand success, drive financial fitness, and thrive in today's competitive market. Our joint endeavors not only offer access to capital and resources but also provide tailored guidance and mentorship, arming small business owners with the insights and support necessary to navigate challenges and seize growth opportunities.”

Houston company's sustainable oil product reaches milestone production capacity 5 years early

overachieving

Houston-based biotech company Cemvita has achieved a key production goal five years ahead of schedule.

Thanks to technology advancements, Cemvita is now capable of generating 500 barrels per day of sustainable oil from carbon waste at its first commercial plant. As a result, Cemvita has quadrupled output at the Houston plant. The company had planned to reach this milestone in 2029.

Cemvita, founded in 2017, says this achievement paves the way for increased production capacity, improved operational efficiency, and an elevated advantage in the sustainable oil market.

“What’s so amazing about synthetic biology is that humans are just scratching the surface of what’s possible,” says Moji Karimi, co-founder and CEO of Cemvita. “Our focus on the first principles has allowed us to design and create new biotech more cheaply and faster than ever before.”

The production achievement follows Cemvita’s recent breakthrough in development of a solvent-free extraction bioprocess.

In 2023, United Airlines agreed to buy up to one billion gallons of sustainable aviation fuel from Cemvita’s first full-scale plant over the course of 20 years.

Cemvita’s investors include the UAV Sustainable Flight Fund, an investment arm of Chicago-based United; Oxy Low Carbon Ventures, an investment arm of Houston-based energy company Occidental Petroleum; and Japanese equipment and machinery manufacturer Mitsubishi Heavy Industries.

Tech disruptions sparked by Texas co.'s update highlight the fragility of globally connected technology

Airlines, banks, hospitals and other risk-averse organizations around the world chose cybersecurity company CrowdStrike to protect their computer systems from hackers and data breaches.

But all it took was one faulty CrowdStrike software update to cause global disruptions Friday that grounded flights, knocked banks and media outlets offline, and disrupted hospitals, retailers and other services.

“This is a function of the very homogenous technology that goes into the backbone of all of our IT infrastructure,” said Gregory Falco, an assistant professor of engineering at Cornell University. “What really causes this mess is that we rely on very few companies, and everybody uses the same folks, so everyone goes down at the same time.”

The trouble with the update issued by CrowdStrike and affecting computers running Microsoft's Windows operating system was not a hacking incident or cyberattack, according to CrowdStrike, which apologized and said a fix was on the way.

But it wasn't an easy fix. It required “boots on the ground” to remediate, said Gartner analyst Eric Grenier.

“The fix is working, it’s just a very manual process and there’s no magic key to unlock it,” Grenier said. “I think that is probably what companies are struggling with the most here.”

While not everyone is a client of CrowdStrike and its platform known as Falcon, it is one of the leading cybersecurity providers, particularly in transportation, healthcare, banking and other sectors that have a lot at stake in keeping their computer systems working.

“They’re usually risk-averse organizations that don’t want something that’s crazy innovative, but that can work and also cover their butts when something goes wrong. That’s what CrowdStrike is,” Falco said. “And they’re looking around at their colleagues in other sectors and saying, ‘Oh, you know, this company also uses that, so I’m gonna need them, too.’”

Worrying about the fragility of a globally connected technology ecosystem is nothing new. It's what drove fears in the 1990s of a technical glitch that could cause chaos at the turn of the millennium.

“This is basically what we were all worried about with Y2K, except it’s actually happened this time,” wrote Australian cybersecurity consultant Troy Hunt on the social platform X.

Across the world Friday, affected computers were showing the “blue screen of death” — a sign that something went wrong with Microsoft's Windows operating system.

But what's different now is “that these companies are even more entrenched,” Falco said. "We like to think that we have a lot of players available. But at the end of the day, the biggest companies use all the same stuff.”

Founded in 2011 and publicly traded since 2019, CrowdStrike describes itself in its annual report to financial regulators as having “reinvented cybersecurity for the cloud era and transformed the way cybersecurity is delivered and experienced by customers.” It emphasizes its use of artificial intelligence in helping to keep pace with adversaries. It reported having 29,000 subscribing customers at the start of the year.

The Austin, Texas-based firm is one of the more visible cybersecurity companies in the world and spends heavily on marketing, including Super Bowl ads. At cybersecurity conferences, it's known for large booths displaying massive action-figure statues representing different state-sponsored hacking groups that CrowdStrike technology promises to defend against.

CrowdStrike CEO George Kurtz is among the most highly compensated in the world, recording more than $230 million in total compensation in the last three years. Kurtz is also a driver for a CrowdStrike-sponsored car racing team.

After his initial statement about the problem was criticized for lack of contrition, Kurtz apologized in a later social media post Friday and on NBC's “Today Show.”

“We understand the gravity of the situation and are deeply sorry for the inconvenience and disruption,” he said on X.

Richard Stiennon, a cybersecurity industry analyst, said this was a historic mistake by CrowdStrike.

“This is easily the worst faux pas, technical faux pas or glitch of any security software provider ever,” said Stiennon, who has tracked the cybersecurity industry for 24 years.

While the problem is an easy technical fix, he said, it’s impact could be long-lasting for some organizations because of the hands-on work needed to fix each affected computer. “It’s really, really difficult to touch millions of machines. And people are on vacation right now, so, you know, the CEO will be coming back from his trip to the Bahamas in a couple of weeks and he won’t be able to use his computers.”

Stiennon said he did not think the outage revealed a bigger problem with the cybersecurity industry or CrowdStrike as a company.

“The markets are going to forgive them, the customers are going to forgive them, and this will blow over,” he said.

Forrester analyst Allie Mellen credited CrowdStrike for clearly telling customers what they need to do to fix the problem. But to restore trust, she said there will need to be a deeper look at what occurred and what changes can be made to prevent it from happening again.

“A lot of this is likely to come down to the testing and software development process and the work that they’ve put into testing these kinds of updates before deployment,” Mellen said. “But until we see the complete retrospective, we won’t know for sure what the failure was.”